Is UiPath Stock A Buy After Falling Despite A Raised Outlook?
UiPath (PATH) sells software that brings AI agents, robots, and people together to run business processes. Its Q2 FY2027 results beat management’s guidance and the fiscal 2027 outlook went up, yet the shares fell 16.6% on September 4, the first trading day after the report, while the S&P 500 slipped 0.4%. The earnings call also carried an analyst’s question about a new AI model said to be far better at workflow jobs.
Did UiPath Give Sellers A Reason In Its Numbers?
The recurring business kept improving. ARR, the subscription run-rate UiPath manages by, reached $1.938 billion, up 12%, and the $37 million added in the quarter topped the $31 million added a year earlier. Dollar-based net retention rose to 109%, so customers from a year earlier now carry 9% more ARR, net of cutbacks and cancellations.
Profit and the outlook moved with it. Revenue was $410 million, up 13%, and non-GAAP operating income reached $89 million, a 22% margin. Management raised its fiscal 2027 non-GAAP operating income target to about $445 million from $430 million, and lifted the fiscal 2027 revenue guide to about $1.79 billion from a prior guide of about $1.78 billion.
Adjusted free cash flow was softer, at $31 million against $45 million a year earlier, which management tied mainly to the timing of tax-related payments. The reported figures leave the analyst’s AI question open.
Does UiPath Lose Work As AI Models Improve?
The CEO’s answer starts from a limit: AI models cannot learn on the job, so every request has to spell out how the whole enterprise works. Anything automation can do should run as automation, the CEO argues, because it is exact, reliable, tokenless and cheaper, with AI working inside that frame.
Deals in the quarter lean that way. AI was part of 18 of the 20 largest deals, and by the CEO’s account a leading financial institution chose UiPath over other orchestration providers because Maestro, UiPath’s orchestration product, alone could run across the institution’s homegrown applications within its compliance rules. Separately, Cognizant will embed UiPath Test Cloud in its testing services.
Management put no number on the AI business. Asked how much net new ARR comes from AI products, it gave none, and the CEO said agentic pricing is still being tested.
What Comes Next For UiPath’s AI Case?
The customer counts lean toward the largest enterprises, where management is pushing. Customers with $1 million or more of ARR rose 21% to 387. UiPath ended the quarter with roughly 10,350 customers, and attrition stayed concentrated in the smallest accounts.
The next test is ARR as of October 31, guided to $1.992 billion to $1.997 billion. Before that, the Investor Day on September 22 will cover long-term strategy. Q2 FY2027 improved recurring revenue and profit records without settling the AI question.
Buyers weighing the drop can check how earlier dips in the stock played out. UiPath’s market value is about $7.2 billion, and over the 52 weeks before the report, the stock traded between $9.20 and $19.29.
Should Your Money Ride On UiPath Winning The AI Argument?
Perhaps, if you expect big enterprises to keep paying for exact, cheaper automation as AI models improve. Even then, a stock tied to one open debate is a single bet, and the Trefis High Quality Portfolio spreads money across businesses with sustainable revenue growth, strong margins and cash generation. That portfolio has a track record of outpacing the three major indices.